REMATIQ

Image for REMATIQ

Overview

REMATIQ is a Berlin-based company specializing in AI-driven solutions for automating product compliance in the medical technology sector. Founded in 2023 by David Boutellier and Florian Scherer, the company focuses on simplifying the complex landscape of regulatory processes to expedite the market launch of MedTech innovations. Recently, REMATIQ has raised €5.4 million in a Seed funding round led by Project A Ventures, Amino Collective, and HelloWorld, positioning itself to enhance its AI technology and expand its market reach.

Recent Developments

  • April 10, 2025: REMATIQ announced securing a €5.4 million Seed funding round aimed at advancing its AI capabilities and scaling operations across Europe and the United States. The funding round was led by Project A Ventures, with participation from Amino Collective and HelloWorld. Prominent angels like Boris Lokschin and Timo Fleßner also joined this round.
  • April 2025: The company emphasized its mission to transform MedTech compliance, turning regulatory requirements into an advantage rather than a hindrance. Its AI-native platform streamlines compliance workflows, reducing the documentation effort by up to 90% and significantly lowering non-compliance risks.
  • February 2025: Featured in several startup spotlights and media outlets as a promising venture revolutionizing the MedTech industry with AI-powered tools.

Company Information

AttributeInformation
Founding Date2023
HeadquartersBerlin, Germany
FoundersDavid Boutellier, Florian Scherer
RevenueNot publicly disclosed
ProfitsNot publicly disclosed
Key InvestorsProject A Ventures, Amino Collective, HelloWorld
IndustryMedical Technology Compliance
Number of EmployeesApprox. 50

Early History

REMATIQ was established in early 2023 amidst the rapidly evolving regulatory landscape of the MedTech industry. Recognizing the time-intensive and error-prone nature of traditional compliance processes, the founders set out to develop an AI-native platform that would automate and streamline these processes. Their vision was to transform compliance from a bottleneck into a seamless, competitive advantage. By leveraging AI, REMATIQ aimed to deliver actionable compliance tasks directly integrated into the development workflows, a visionary move that garnered early attention and traction.

Company Profile and Achievements

REMATIQ operates on a business model that combines software-as-a-service (SaaS) with artificial intelligence to enhance efficiency and innovation within the MedTech regulatory space.

  • AI-Driven Compliance: REMATIQ's platform automates compliance workflows by interpreting complex regulatory requirements and transforming them into structured, machine-readable tasks.
  • Investment and Growth: Since its inception, REMATIQ has secured over €5.4 million in funding, accelerating its technology development and expanding its operational footprint.
  • Collaboration and Innovation: The platform is already utilized by major MedTech companies including B. Braun Group, demonstrating its real-time impact and efficiency.
  • Cost and Time Efficiency: By automating manual compliance tasks, REMATIQ reduces the time spent on regulatory processes by up to 90%, allowing engineers to focus on innovation.

Current Operations and Market Position

REMATIQ is firmly positioned within the niche of MedTech regulatory compliance, leveraging AI to provide a competitive edge in a heavily regulated industry. The company's platform streamlines regulatory workflow management, significantly reducing the risk of non-compliance and speeding up product development cycles. REMATIQ distinguishes itself through its AI-driven approach, integrated solutions, and strong industry partnerships, all contributing to its growing influence in Europe and beyond.

Conclusion

REMATIQ stands at the forefront of transforming the MedTech compliance landscape through its innovative use of artificial intelligence. By addressing complex regulatory challenges, the company not only enhances the speed of bringing new technologies to market but also ensures adherence to stringent safety and quality standards. As REMATIQ continues to scale its operations and refine its technological solutions, it is poised to be a key player in facilitating the growth and innovation of global medical technology advancements.

References

  1. REMATIQ Website
  2. EU Startups Article
  3. Tech Funding News
  4. Maglazana
  5. Tracxn Company Profile
  6. Medical Buyer News
  7. DEALROOM Profile
  8. PitchBook Company Profile